EI
CRMD icon

EAM Investors’s CorMedix CRMD Stock Holding History

EAM Investors’s Portfolio CRMD Stock Details CRMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-158,571
Closed -$1.95M – 277
2025
Q2 		$1.95M Buy
+158,571
New +$1.75M 0.3% 136
2024
Q4 		– Sell
-130,036
Closed -$1.05M – 280
2024
Q3 		$1.05M Buy
130,036
+25,142
+24% +$136K 0.16% 160
2024
Q2 		$454K Buy
+104,894
New +$533K 0.07% 235
2021
Q1 		– Sell
-120,002
Closed -$892K – 360
2020
Q4 		$892K Buy
+120,002
New +$816K 0.15% 276
2019
Q2 		– Sell
-146,472
Closed -$1.38M – 262
2019
Q1 		$1.38M Buy
146,472
+27,587
+23% +$249K 0.34% 136
2018
Q4 		$767K Sell
118,885
-25,854
-18% -$173K 0.21% 209
2018
Q3 		$701K Buy
+144,739
New +$356K 0.1% 275
2015
Q2 		– Sell
-31,106
Closed -$1.53M – 329
2015
Q1 		$1.53M Buy
+31,106
New +$738K 0.18% 227

Other funds holding CRMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

EAM Investors's CRMD Position: Q3 2025 in Review

EAM Investors sold out of CorMedix (CRMD) in Q3 2025, closing a stake of 158,571 shares — an estimated $1.95M sold.

EAM Investors first reported a position in CRMD in Q1 2015 and held it in 8 quarters. The position peaked at $1.95M in Q2 2025. 190 funds tracked by Wall St. Rank hold CRMD as of Q3 2025.

  • EAM Investors reported no remaining CorMedix position as of Q3 2025 after selling out during the quarter.
  • EAM Investors sold 158,571 CorMedix shares in Q3 2025, an estimated $1.95M.
  • EAM Investors first reported a position in CorMedix in Q1 2015 and held it in 8 quarters.
  • EAM Investors's CorMedix position peaked at $1.95M in Q2 2025.
  • 190 funds tracked by Wall St. Rank held CorMedix as of Q3 2025.

Based on EAM Investors's 13F filing for Q3 2025, filed 14 Nov 2025.